To include your compound in the COVID-19 Resource Center, submit it here.

Insmed's ALIS meets in Phase III for rare lung infection

Insmed Inc. (NASDAQ:INSM) reported top-line data from the Phase III CONVERT trial in 336 patients with treatment-refractory non-tuberculosis mycobacterial (NTM) lung infection caused by Mycobacterium avium complex (MAC) showing

Read the full 294 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE